Great news for PER, especially considering that other therapies are failing. There is a lot of money at stake here. Pfizer, Sarepta etc will be keen to strike a deal with PER if we can replicate the previous trial data. Worth considering Dr Voits comments from the previous trial…
Professor Thomas Voit MD, Director, NIHR GOSH Biomedical Research Centre, UK had this to say about the trial results and the efficacy being observed in this Phase II trial of ATL1102: “The data certainly suggests an overall ‘stabilisation’ in disease progression at the very least which of itself is a very positive clinical outcome. MRI data confirms the positive changes at a muscular/cellular level and supports the observed physical stabilisation/improvements in muscle strength and function. The consistency of positive clinically relevant effects of ATL1102 treatment across muscle measures of structure, strength and function are very pleasing and provide great encouragement for the treatment of non-ambulant patients with DMD”.
PER Price at posting:
7.4¢ Sentiment: Buy Disclosure: Held
